Aphios®
Presents Its Anti-Infectives Program At Global Technology
Community's 8th Anti-Infectives Partnering And Deal-Making
Infectious Diseases World Summit
Woburn,
MA — November 07, 2011 —Dr. Trevor
P. Castor, President and CEO, Aphios® Corporation, will
present Aphios’ Anti-Infectives Program at the Global
Technology Community’s 8th Annual Anti-Infectives
Conference at the Infectious Diseases World Summit, held
at the Omni Parker House, Boston, MA on November 7th-8th,
2011.
A core component of Aphios’ Anti-Infectives program
is SFS-CFI
virus inactivation technology for enveloped viruses such
as HIV and non-enveloped viruses such as B19 and EMC to
improve the safety of human plasma, plasma products, monoclonal
antibodies and other recombinant proteins.
Aphios also utilizes its unique library of marine organisms,
patented SFS-CXF
technology, and viral and microbial targets to discover
and develop novel anti-infectives.
“To date, our research program has generated several
novel anti-HIV and anti-influenza ‘hits,’ as
well as MRSA and marine anti-plaque leads,” says Dr.
Castor. “Other HIV antiviral therapeutics being researched
include nanoHYP™,
which is a nanoformulation of a photo-sensitive molecule,
and a chemiluminescent substrate that acts like a molecular
flashlight to activate photo-sensitive molecules to kill
HIV and other pathogens inside the body as well as ex vivo
in red blood cells; and Albaspheres™, an oral nanoformulation
of betulinic acid that works as an HIV maturation inhibitor.”
Aphios has developed and patented an HIV/AIDS therapeutic
vaccine based on inactivated HIV using SFS-CFI technology,
and a vaccine
adjuvant technology consisting of polymer nanospheres
using its proprietary and patented SuperFluids™
PNS technology for anthrax rPA and other subunit vaccines.
Aphios’ lead anti-infective therapeutic product in
development is APH-0812,
a combination therapy consisting of Protein Kinase C (PKC)
modulators and Histone Deacetylase (HDAC) inhibitors, designed
to reactivate latent HIV reservoirs so that HIV can be eliminated
by antiviral therapy and eradicated from the body.
“Our researchers have found that the PKC modulator
down regulates the expression of the HIV-1 receptors CD4
and CXCR4 and thus is a candidate for treating HIV-1 latency,”
explains Dr. Castor. “We have also discovered that
the PKC modulator synergizes with HDAC inhibitors to antagonize
HIV-1 latency.” Aphios hopes to announce a human clinical
trial of APH-0812 in Spain in the first or second quarter
of 2012.
Aphios® Corporation is a green biotechnology company
developing enabling technology platforms for improved drug
discovery and manufacturing, nanotechnology drug delivery
and pathogenic drug safety. Based on these platforms, Aphios
is developing enhanced therapeutic products for health maintenance,
disease prevention and the treatment of certain cancers,
infectious diseases and central nervous system disorders,
such as Alzheimer ’s disease.
###
